Books
in black and white
Main menu
Share a book About us Home
Books
Biology Business Chemistry Computers Culture Economics Fiction Games Guide History Management Mathematical Medicine Mental Fitnes Physics Psychology Scince Sport Technics
Ads

biopharmaceuticals biochemistry and biotecnology - Walsh G.

Walsh G. biopharmaceuticals biochemistry and biotecnology - John Wiley & Sons, 2003. - 572 p.
ISBN 0-470-84327-6
Download (direct link): biochemistryandbiotechnology2003.pdf
Previous << 1 .. 134 135 136 137 138 139 < 140 > 141 142 143 144 145 146 .. 292 >> Next

CYTOKINES: INTERLEUKINS AND TUMOUR NECROSIS FACTOR 253
Fehniger, T. et al. (2002). Interleukin-2 and interleukin 15: immunotherapy for cancer. Cytokine Growth Factor Rev. 13(2), 169-183.
Fickenscher, H. et al. (2002). The interleukin-10 family of cytokines. Trends Immunol. 23(2), 89-96.
Fry, J. & Mackall, C. (2002). Interleukin-7: from bench to clinic. Blood 99(11), 3892-3904.
Jeal, W. & Goa, K. (1997). Aldesleukin (recombinant interleukin-2) — a review of its pharmacological properties, clinical efficacy and tolerability in patients with renal cell carcinoma. Biodrugs 7(4), 285-317.
Komschlies, K. et al. (1995). Diverse immunological and haematological effects of interleukin-7: implications for clinical application. J. Leukocyte Biol. 58, 623-631.
Martin, M. & Falk, W. (1997). The interleukin-1 receptor complex and interleukin 1 signal transduction. Eur. Cytokine Network 8(1), 5-17.
Noble, S. & Goa, K. (1997). Aldesleukin (recombinant interleukin-2) — a review of its pharmacological properties, clinical efficacy and tolerability in patients with metastic melanoma. Biodrugs 7(5), 394-422.
Powers, R., Garrett, D.S., March, C.J. et al. (1992). Three-dimensional solution structure of human interleukin-4 by multidimensional heteronuclear magnetic resonance spectroscopy. Science 256, 1673.
Renauld, J. et al. (1995). Interleukin-9 and its receptor: involvement in mast cell differentiation and T cell oncogenesis.
J. Leukocyte Biol. 57, 353-359.
Ryan, J. (1997). Interleukin-4 and its receptor — essential mediators of the allergic response. J. Allergy Clin. Immunol. 99(1), 1-5.
Scott, P. (1993). IL-12: initiation cytokine for cell mediated immunity. Science 260, 496-497.
Simpson, R. et al. (1997). Interleukin-6 structure-function relationships. Protein Sci. 6(5), 929-955.
Wigginton, J. & Wiltrout, R. (2002). IL-12/IL-2 combination cytokine therapy for solid tumors: translation from benchside to bedside. Expert Opin. Biol. Therapy 2(5), 513-524.
Tumour necrosis factor
Argiles, J. & Lepezsoriano, F. (1997). Cancer cachexia — a key role for TNF. Int. J. Oncol. 10(3), 565-572.
Bodmer, J. et al. (2002). The molecular architecture of the TNF superfamily. Trends Biochem. Sci. 27(1), 19-26.
Bondeson, J. et al. (2000). TNF as a therapeutic agent. Immunologist 8(6), 136-140.
Crowe, P. et al. (1994). A lymphotoxin-b-specific receptor. Science 264, 707-709.
Darnay, B. & Aggarwal, B. (1997). Early events in TNF signalling — a story of associations and disassociations. J. Leukocyte Biol. 61(5), 559-566.
Dellinger, R. et al. (1997). From the bench to the bedside — the future of sepsis research. Chest 111(3), 744-753.
Eck, M.J. & Sprang, S.R. (1989). The structure of tumor necrosis factor-a at 2.6 A resolution. Implications for receptor binding. J. Biol. Chem. 264, 17595.
Feldmann, M. et al. (1997). Anti-tumor necrosis factor-a therapy of rheumatoid arthritis. Adv. Immunol. 64, 283-350.
Hohlfeld, R. (1997). Biotechnological agents for the immunotherapy of multiple sclerosis — principles, problems and perspectives. Brain 120, 865-916.
McDermot, M. (2001). TNF and TNFR biology in health and disease. Cell. Mol. Biol. 47(4), 619-635.
MacEwan, D. (2002). TNF receptor subtype signalling: differences and cellular consequences. Cell. Signalling 14(6), 477-492.
McGeer, E. & McGeer, P. (1997). Inflammatory cytokines in the CNS — possible role in the pathogenesis of neurodegenerative disorders and therapeutic implications. CNS Drugs 7(3), 214-228.
Maini, R. et al. (1997). TNF blockade in rheumatoid arthritis — implications for therapy and pathogenesis. APMIS 105(4), 257-263.
Moreland, W. et al. (1997). Biological agents for treating rheumatoid arthritis — concepts and progress. Arthritis Rheumatism 40(3), 397-409.
Terranova, P. (1997). Potential roles of tumor necrosis factor-a in follicular development, ovulation and the life-span of the corpus luteum. Domest. Anim. Endocrinol. 14(1), 1-15.
Tracey, K. & Cerami, A. (1994). Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Ann. Rev. Med. 45, 491-503.
Vandenabeele, P. et al. (1995). Two tumor necrosis factor receptors: structure and function. Trends Cell Biol. 5, 392-399.
Chapter 6 Haemopoietic growth factors
Blood consists of red and white cells which, along with platelets, are all suspended in plasma. All peripheral blood cells are derived from a single cell type: the stem cell (also known as a pluripotential, pluripotent or haemopoietic stem cell). These stem cells reside in the bone marrow, alongside additional cell types, including (marrow) stromal cells. Pluripotential stem cells have the capacity to undergo prolonged or indefinite self-renewal. They also have the potential to differentiate, thereby yielding the range of cells normally found in blood (Table 6.1). This process, by which a fraction of stem cells are continually ‘deciding’ to differentiate (thus continually producing new blood cells and platelets to replace aged cells), is known as haemopoiesis.
Previous << 1 .. 134 135 136 137 138 139 < 140 > 141 142 143 144 145 146 .. 292 >> Next